BCS II waiver approach [Dissolution / BCS / IVIVC]

posted by yuvaneshwari – India, 2019-01-23 06:09 (675 d 12:08 ago) – Posting: # 19801
Views: 2,042

Dear All,

Drug compound is BCS-II [dosage form is solution filled in capsule], and objective is to formulate with Q1 & Q2 sameness to that of Reference. Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.

In the above scenario, can we consider for BCS based waiver approach ?

Complete thread:

Activity
 Admin contact
21,216 posts in 4,427 threads, 1,482 registered users;
online 16 (0 registered, 16 guests [including 16 identified bots]).
Forum time: Saturday 18:17 CET (Europe/Vienna)

Science may be described as the art of systematic over-simplification –
the art of discerning what we may with advantage omit.    Karl R. Popper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5